---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003323"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-26T00:07:47.799866+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Celldex Q1 net loss $0.49/share; cash $380.5M; barzolvolimab Ph2 starts Q2 2022

## Summary
- Net loss of $23.1M ($0.49 per share) vs $16.5M ($0.42) a year ago; revenue fell to $0.2M from $0.7M.
- Cash, cash equivalents and marketable securities $380.5M at March 31, 2022; sufficient to fund operations through 2025.
- R&D expenses increased to $17.1M from $12.7M; G&A expenses $6.9M vs $4.1M, driven by clinical and commercial planning.
- Phase 2 studies of barzolvolimab in chronic spontaneous and inducible urticaria to initiate Q2 2022; Phase 1b CSU data submitted to EAACI.
- Barzolvolimab expansion into eosinophilic esophagitis with Phase 2 planned Q4 2022; enrollment continues in prurigo nodularis and inducible urticaria.

## SEC filing metadata
- accession: 0001171843-22-003323
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/0001171843-22-003323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184322003323/f8k_050522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003323
- JSON: https://secwatch.observer/filing/0001171843-22-003323.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.